Non-exclusive pharmaceutical rebate agreement Brinzolamid/Timolol
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Timolol (amtlicher ATC-Code: S01ED67)
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...
The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Dec 31, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Dec 2026
- Conclude non-exclusive rebate agreements for the pharmaceutical product Brinzolamid/Timolol (eye drops).
- Supply of the product to pharmacies in the regions of Saxony and Thuringia (Germany) as prescribed by physicians.
Show full summary
This is an Open-House model (non-exclusive) for concluding pharmaceutical rebate agreements for the active substance Brinzolamid/Timolol (ATC code S01ED67) under §130a Abs. 8 SGB V. The procedure is open to all interested pharmaceutical companies that meet participation requirements. No individual negotiations, no exclusivity, and no guaranteed minimum purchase quantities. The agreement ends no later than 31.12.2026, but may terminate earlier if exclusive agreements are concluded. Participation requests can be submitted from 03.12.2024, with multiple submission deadlines as per the document 'Einreichungsfristen'. Communication and submission are electronic via DTVP. The buyer is AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen.
Risks
No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...
The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur within the meaning of §4 Abs. 18 AMG.
Eligibility
- Submission of a declaration on absence of exclusion grounds (Anlage 'Eigenerklärung zum Nichtvorliegen von Ausschlussgründen').
Administrative
- Declaration regarding EU Russia sanctions (Anlage 'Eigenerklärung Russlandsanktionen').
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive pharmaceutical rebate agreement Brinzolamid/Timolol
Single lot covering the entire scope: non-exclusive rebate agreements for Brinzolamid/Timolol. No lot-specific details beyond the overall description.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Brinzolamid/Timolol (amtlicher ATC-Code: S01ED67)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 10 Nov 2024
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 683594-2024
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No minimum purchase quantities are guaranteed. Actual demand depends on patient numbers, prescribing habits, and pharma...
The buyer may terminate the Open-House procedure early if exclusive agreements are concluded, which could happen 8-12 m...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications